Azathioprine

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Civil service commission, Eating, Diagnosis, Azathioprine, Disease, Dermatomyositis, Risk, Rash, Inflammation, Patient, Committee, Knowledge, Tissue, Regulation, EMA, IRIS, Mouth, European, Skin, COMP, Heart, Sponsor, European Commission, Immune system, Safety, Muscle weakness, Skeletal muscle, Stomach, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Most Effective Atopic Dermatitis Treatments May Also Be Most Harmful

Retrieved on: 
Wednesday, February 21, 2024
Atopic dermatitis, AAAAI, MEDLINE, Research, Multimedia, Conjunctivitis, Meta-analysis, Ciclosporin, Physician, Quality of life, Asthma, Methotrexate, Skin, Annual general meeting, GREAT, Light, Sleep, Patient, Journal, Dermatitis, The Hills Shire, Azathioprine, American Academy, Pharmaceutical industry

"Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.

Key Points: 
  • "Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.
  • Competing treatment options exist for atopic dermatitis, but uncertainty regarding their comparative effectiveness still remains, the study showed.
  • Researchers examined the benefits and harms of all systemic and phototherapy treatments for atopic dermatitis in this network meta-analysis.
  • In randomized, controlled trials addressing systemic and phototherapy treatments for atopic dermatitis from MEDLINE, EMBASE, CENTRAL, Web of Science and GREAT, researchers performed Bayesian random-effects network meta-analyses on atopic dermatitis severity, itch severity, sleep disturbance, quality of life, exacerbations and adverse events.

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Contraindication, AZA, Axial spondyloarthritis, Rash, Tissue, ACR20, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Adolescence, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Nonsteroidal anti-inflammatory drug, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Select, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Child, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Contraindication, AZA, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Psoriasis, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Retrieved on: 
Thursday, October 26, 2023
Nexus, Patient, FDA, Academy of Managed Care Pharmacy, Research, Standard of care, Cyclophosphamide, Food, Outcomes research, ClinicoEconomics and Outcomes Research, Treatment, NS, Adrenocorticotropic hormone (medication), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, D20, QALY, Poster, Nephrotic syndrome, Congenital nephrotic syndrome, Adrenocorticotropic hormone, Sarcoidosis, Chlorambucil, Rituximab, Symphony, ICER, SOC, Calcineurin, AMCP, Azathioprine, Diagnosis, Proteinuria, Pharmaceutical industry, Medical imaging, Mallinckrodt

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health economics outcomes research on Acthar® Gel (repository corticotropin injection) for patients with advanced symptomatic sarcoidosis and nephrotic syndrome (NS)1,2 at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 in Orlando, FL October 16-19, 2023.

Key Points: 
  • Patients were monitored at the end of a three-month cycle for a partial or complete response.
  • The full data manuscript from this study was published in ClinicoEconomics and Outcomes Research on October 17, 2023.
  • "We are pleased to have shared our latest health economics research on Acthar Gel.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to Acthar.